Standard Biotools Filter Stocks by Fundamentals
| LAB Stock | USD 0.99 -0.03 -2.94% |
| = | null |
Latest Standard Biotools Total Revenue Growth Pattern
| Total Revenue | 10 Years Trend |
|
Total Revenue |
| Timeline |
Total Revenue Trend Statistics
Standard Biotools' Total Revenue carries a CV of 39.8% across 15 periods, indicating elevated dispersion relative to the mean. Linear regression yields an R-squared of 0.38, pointing to a moderate linear trend with partial explanatory power.| Arithmetic Mean | 97,901,996 | |
| Geometric Mean | 83,742,747 | |
| Coefficient Of Variation | 39.81 | |
| Mean Deviation | 28,033,063 | |
| Median | 104,446,000 | |
| Standard Deviation | 38,971,177 | |
| Sample Variance | 1518.8T | |
| Range | 168M | |
| R-Value | 0.62 | |
| Mean Square Error | 1005.7T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 4,752,175 | |
| Total Sum of Squares | 24300T |
Standard Biotools Total Revenue History
Standard Biotools reports Total Revenue from 2012 through 2026 across 15 observations, beginning at 52.33 million and ending at 91.02 million.Correlation of Total Revenue With Other Accounts
Cross-account correlations for Standard Biotools' Total Revenue measure how closely related line items have moved together historically. Correlation does not establish cause and effect.| 0.34 | 0.42 | -0.15 | -0.76 | -0.04 | ||
| 0.34 | 0.93 | -0.55 | -0.24 | 0.49 | ||
| 0.42 | 0.93 | -0.5 | -0.39 | 0.29 | ||
| -0.15 | -0.55 | -0.5 | 0.18 | -0.89 | ||
| -0.76 | -0.24 | -0.39 | 0.18 | 0.06 | ||
| -0.04 | 0.49 | 0.29 | -0.89 | 0.06 |
Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Current Deferred Revenue | $38.95 million | $40.9 million | |
| Cost Of Revenue | $42.79 million | $40.37 million | |
| Stock Based Compensation To Revenue | 0.35x | 0.36x | |
| Sales General And Administrative To Revenue | 1.29x | 1.01x | |
| Research And Ddevelopement To Revenue | 0.3x | 0.59x | |
| Capex To Revenue | 0.1x | 0.08x | |
| Revenue Per Share | 0.22 | 0.21 | |
| Ebit Per Revenue | $-1.09 | $-1.15 |
Historical and Projected Quarterly Revenue of Standard
Revenue forecast analysis for Standard Biotools ties forward estimates to past delivery patterns. Ongoing revenue misses versus estimates may mean the market has overstated Standard Biotools' growth trend. Standard Biotools currently reports annual revenue of 85.3 M. The mix of organic and inorganic revenue drivers shapes the sustainability of Standard Biotools' growth trajectory. With earnings per share at -0.13, revenue trends directly affect per-share returns.
What Drives Revenue
The correlation matrix maps how Revenue co-moves with Standard Biotools' other financial accounts across reporting periods. Positive correlations suggest shared drivers; negative correlations may reflect natural offsets within Standard Biotools' financial structure.
Click cells to compare fundamentals
| Competition |
Standard Current Deferred Revenue
Current Deferred Revenue | $40.9 million |
How Key Fundamentals Interact
Did You Try This?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Important Fundamentals
| Return On Equity TTM | -0.0986 | |||
| Return On Asset TTM | -0.0805 | |||
| Profit Margin TTM | 0.91 | |||
| Operating Margin TTM | -0.45 | |||
| Current Valuation | -27.51 M | |||
| Shares Outstanding | 390.37 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 76.85 % | |||
| Number Of Shares Shorted | 11.82 M | |||
| Price To Earnings TTM | -2.52 X | |||
| Price To Book TTM | 0.71 X | |||
| Price To Sales TTM | 4.57 X | |||
| Revenue TTM | 85.33 M | |||
| Gross Profit TTM | 45.95 M | |||
| EBITDA TTM | -94.96 M | |||
| Net Income TTM | -74.9 M | |||
| Cash And Equivalents TTM | 81.31 M | |||
| Cash Per Share TTM | 2.68 X | |||
| Total Debt TTM | 30.83 M | |||
| Debt To Equity TTM | 0.38 % | |||
| Current Ratio TTM | 5.87 X | |||
| Book Value Per Share TTM | 1.44 X | |||
| Cash Flow From Operations TTM | -74.35 M | |||
| Short Ratio TTM | 3.88 X | |||
| Earnings Per Share | -0.13 X | |||
| Price To Earnings To Growth | 0.31 X | |||
| Target Price | 1.55 | |||
| Number Of Employees | 385 | |||
| Trailing Beta | 1.31 | |||
| Market Capitalization TTM | 394.27 M | |||
| Total Asset TTM | 567.75 M | |||
| Retained Earnings TTM | -1.26 B | |||
| Working Capital TTM | 345.96 M | |||
| Net Asset | 567.75 M |
Financial Profile and Methodology
For a clinical-stage company like Standard Biotools, traditional profitability metrics are secondary to capital adequacy and dilution risk. As a small-cap development-stage company, negative earnings are expected and do not carry the same signal as for mature businesses. Standard Biotools financial statements report revenue of 85.33 million, EPS loss of 0.13, negative operating margin of 44.53%, current ratio of 5.87 as of the latest reporting period.
Standard Biotools metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board